Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD19 CAR T cells PBCAR19B

A preparation of allogeneic T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19), a single short hairpin RNA (shRNA) that disrupts the expression of beta-2 microglobulin (B2M) component of the class 1 major histocompatibility complex (MHC) molecules, and a HLA-E gene, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR T cells PBCAR19B specifically recognize and bind to CD19-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-expressing tumor cells. The downregulation of the expression of the class 1 MHC molecule component B2M by shRNA and the HLA-E gene decrease the number of CAR T cells that are rejected and killed by natural killer (NK) and cytotoxic T cells. CD19 antigen is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CD19 CAR T cells PBCAR19B
allogeneic CD19-targeting CAR-T cells PBCAR19B
Code name:PBCAR19B
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search